The role of Aflibercept in the management of age-related macular degeneration

Expert Opinion on Biological Therapy

Volumn 16, Issue 5, 2016, Pages 699-709

  Hassan, Muhammad ^a   Afridi, Rubbia ^a   Sadiq, Mohammad Ali ^a   Soliman, Mohamed Kamel ^a,b   Agarwal, Aniruddha ^a   Sepah, Yasir Jamal ^a   Do, Diana V ^a   Nguyen, Quan Dong ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b ASSIUT UNIVERSITY   (Egypt)

Author keywords

aflibercept; Age related macular degeneration; anchor; anti vegf therapy; catt; clinicaltrials; degeneration; marina; vegf; view

Indexed keywords

AFLIBERCEPT; PLACEBO; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; HYBRID PROTEIN; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADVERSE DRUG REACTION; AGE RELATED MACULAR DEGENERATION; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRECLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); ANTAGONISTS AND INHIBITORS; PSYCHOLOGY; QUALITY OF LIFE; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CLINICAL TRIALS AS TOPIC; HUMANS; QUALITY OF LIFE; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84964388857     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2016.1167182     Document Type: Article

References (58)

1. Klein R, Peto T, Bird A, et al. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004 Mar; 137 (3): 486-495. doi: 10.1016/j.ajo.2003.11.069.
2. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014 Feb; 2 (2): e106e116. doi: 10.1016/S2214-109X(13)70145-1.
3. Friedman DS, OColmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004 Apr; 122 (4): 564-572. doi: 10.1001/archopht.122.4.564.
4. Prevalence of age-related macular degeneration in the United States. [cited 2015 Oct 2]. Available from: http://www.who.int/blindness/causes/priority/en/index8.html
5. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984 Nov; 102 (11): 1640-1642.
6. Verteporfin In Photodynamic Therapy Study G. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001 May; 131 (5): 541-560.
7. Bressler NM. Treatment of age-related macular degeneration with photodynamic therapy study G. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001 Feb; 119 (2): 198-207.
8. Miller JW. Age-related macular degeneration revisited-piecing the puzzle: the LXIX Edward Jackson memorial lecture. Am J Ophthalmol. 2013 Jan; 155 (1): 135e13. doi: 10.1016/j.ajo.2012.10.018.
9. McKibbin M, Devonport H, Gale R, et al. AFLibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel. Eye. 2015 Jul; 29 (Suppl 1): S1-S11. doi: 10.1038/eye.2015.77.
10. Veikkola T, Karkkainen M, Claesson-Welsh L, et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000 Jan 15; 60 (2): 203-212.
11. Lee SH, Jeong D, Han Y-S, et al. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res. 2015 Jul; 89 (1): 1-8. doi: 10.4174/astr.2015.89.1.1.
12. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003 Jul; 44 (7): 3186-3193. doi: 10.1167/iovs.02-1092.
13. Huo X, Li Y, Jiang Y, et al. Inhibition of ocular neovascularization by co-inhibition of VEGF-A and PLGF. Cell Physiol Biochem. 2015; 35 (5): 1787-1796. doi: 10.1159/000373990.
14. Al-Halafi AM. Vascular endothelial growth factor trap-eye and trap technology: AFLibercept from bench to bedside. Oman J Ophthalmol. 2014 Sep; 7 (3): 112-115. doi: 10.4103/0974-620X.142591.
15. Miller JW, Le Couter J, Strauss EC, et al. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013 Jan; 120 (1): 106-114. doi: 10.1016/j.ophtha.2012.07.038.
16. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012 Jun; 15 (2): 171-185. doi: 10.1007/s10456-011-9249-6.
17. Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina. 2011 Oct; 31 (9): 1877-1884. doi: 10.1097/IAE.0b013e318217373c.
18. Krohne TU, Liu Z, Holz FG, et al. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012 Oct; 154 (4): 682686.e2. doi: 10.1016/j.ajo.2012.03.047.
19. Thomas M, Mousa SS, Mousa SA. Comparative effectiveness of AFLibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmology. 2013; 7: 495-501. doi: 10.2147/OPTH.S29974.
20. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol. 2008 May; 92 (5): 667-668. doi: 10.1136/bjo.2007.134874.
21. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995 Nov 7; 92 (23): 10457-10461.
22. Cao J, Zhao L, Li Y, et al. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap. Invest Ophthalmol Vis Sci. 2010 Nov; 51 (11): 6009-6017. doi: 10.1167/iovs.09-4956.
23. Saishin Y, Takahashi K, Lima E Silva R, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003 May; 195 (2): 241-248. doi: 10.1002/jcp.10246.
24. Nork TM, Dubielzig RR, Christian BJ, et al. Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates. Arch Ophthalmol. 2011 Aug; 129 (8): 1042-1052. doi: 10.1001/archophthalmol.2011.210.
25. Oliveira HB, Sakimoto T, Javier JAD, et al. VEGF Trap(R1R2) suppresses experimental corneal angiogenesis. Eur J Ophthalmol. 2010 JanFeb; 20 (1): 48-54.
26. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006 Sep; 113 (9): 1522e122 e14. doi: 10.1016/j.ophtha.2006.05.055.
27. Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology. 2009 Nov; 116 (11): 21418e1.
28. Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology. 2011 Jun; 118 (6): 1098-1106. doi: 10.1016/j.ophtha.2011.03.020.
29. Brown DM, Heier JS, Ciulla T, et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology. 2011 Jun; 118 (6): 1089-1097. doi: 10.1016/j.ophtha.2011.02.039.
30. Heier JS, Brown DM, Chong V, et al. VIEW 1 and VIEW 2 study groups. Intravitreal AFLibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec; 119 (12): 2537-2548.
31. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal AFLibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014 Jan; 121 (1): 193-201. doi: 10.1016/j.ophtha.2013.08.011.
32. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009 Jan; 116 (1): 5765e5.
33. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5; 355 (14): 1419-1431.
34. Group CR, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19; 364 (20): 1897-1908.
35. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013 Oct 12; 382 (9900): 1258-1267.
36. Efficacy of Ranibizumab Prn Treatment Compared to AFLibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD (SALT), NCT01958918. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01958918
37. Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal AFLibercept Injection) (RE-VIEW), NCT01722045. Available from: https://clinicaltrials.gov/ct2/show/NCT01722045
38. VITAL-Individualising Therapy for Neovascular AMD With AFLibercept, NCT02441816. Available from: https://clinicaltrials.gov/ct2/show/NCT02441816
39. A Pharmacokinetic Study of Intravitreal AFLibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (DRAW), NCT02204683. Available from: https://clinicaltrials.gov/ct2/show/NCT02204683
40. A Comparison of Ranibizumab and AFLibercept for the Development of Geographic Atrophy in (Wet) AMD Patients (RIVAL), NCT02130024. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02130024
41. Real Life of AFLibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD (TITAN), NCT02321241. Available from: https://clinicaltrials.gov/ct2/show/NCT02321241
42. Intravitreal AFLibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Monthly Ranibizumab Injections (SHIFT-2), NCT02002377. Available from: https://clinicaltrials.gov/ct2/show/NCT02002377
43. Study of Intravitreal REGN2176-3 in Patients With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) (CAPELLA), NCT02418754. Available from: https://clinicaltrials.gov/ct2/show/NCT02418754?term=REGN2176-3&rank=1
44. Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME), NCT01997164. Available from: https://clinicaltrials.gov/ct2/show/NCT01997164?term=R910-3-OD-1403&rank=1
45. Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012 Jul; 119 (7): 1388-1398. doi: 10.1016/j.ophtha.2012.03.053.
46. Chang AA, Li H, Broadhead GK, et al. Intravitreal AFLibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology. 2014 Jan; 121 (1): 188-192. doi: 10.1016/j.ophtha.2013.08.035.
47. Singh RP, Srivastava SK, Ehlers JP, et al. A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal AFLibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis.AFL. Clin Ophthalmology. 2015; 9: 1759-1766. doi: 10.2147/OPTH.S87043.
48. Wykoff CC, Brown DM, Maldonado ME, et al. AFLibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol. 2014 Jul; 98 (7): 951-955.
49. Wykoff CC, Brown DM, Croft DE, et al. Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. Ophthalmology. 2013 Sep; 120 (9): 19456.e1. doi: 10.1016/j.ophtha.2013.06.030.
50. Brown DM, Chen E, Mariani A, et al. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology. 2013 Feb; 120 (2): 349-354. doi: 10.1016/j.ophtha.2012.08.008.
51. Kawashima Y, Oishi A, Tsujikawa A, et al. Effects of AFLibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie. 2015 Sep; 253 (9): 1471-1477.
52. Grewal DS, Gill MK, Sarezky D, et al. Visual and anatomical outcomes following intravitreal AFLibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye. 2014 Jul; 28 (7): 895-899. doi: 10.1038/eye.2014.101.
53. Sarao V, Parravano M, Veritti D, et al. Intravitreal AFLibercept for choroidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapy. Retina. 2015 Sep 21: 1. doi: 10.1097/IAE.0000000000000751.
54. Bhavsar KV, Freund KB. Retention of good visual acuity in eyes with neovascular age-related macular degeneration and chronic refractory subfoveal subretinal fluid. Saudi J Ophthalmol. 2014 Apr; 28 (2): 129-133. doi: 10.1016/j.sjopt.2014.03.001.
55. Semeraro F, Morescalchi F, Duse S, et al. AFLibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther. 2013; 7: 711-722. doi: 10.2147/DDDT.S40215.
56. Elshout M, Van Der Reis MI, Webers CA, et al. The cost-utility of AFLibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefes archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie. 2014 Dec; 252 (12): 1911-1920.
57. Bhisitkul RB, Mendes TS, Rofagha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol. 2015 May; 159 (5): 91524e2.
58. Grunwald JE, Pistilli M, Ying G-S, et al. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015 Apr; 122 (4): 809-816. doi: 10.1016/j.ophtha.2014.11.007.